UroGen Pharma Ltd. (URGN) reported fourth‑quarter and full‑year 2025 financial results on March 2, 2026, showing total revenue of $109.8 million, a 21% year‑over‑year increase driven by the commercial launch of its new NMIBC therapy ZUSDURI and continued growth of its flagship drug Jelmyto. The company posted a net loss of $153.5 million, or $3.19 per share, reflecting higher manufacturing and commercial expenses associated with ZUSDURI and ongoing R&D investments in next‑generation programs such as UGN‑103 and UGN‑104. Cash, cash equivalents and marketable securities stood at $120.5 million at year‑end, providing a runway for continued investment while it scales ZUSDURI adoption.
In the fourth quarter, UroGen generated $37.8 million in revenue, missing the consensus estimate of $40.7 million. Net loss per share for the quarter was $0.54, slightly better than the estimated loss of $0.51 but still below the analyst expectation of $-0.66. The miss was largely driven by higher SG&A expenses, which rose to $155.1 million from $121.2 million in 2024, and increased R&D spending, which climbed to $67.1 million from $57.1 million. These higher operating costs offset the revenue growth from ZUSDURI’s early launch.
ZUSDURI contributed $15.8 million in net sales in 2025, marking a significant milestone for the first FDA‑approved drug for recurrent low‑grade intermediate‑risk non‑muscle invasive bladder cancer. Management noted that the company is not providing full‑year 2026 sales guidance for ZUSDURI at this time, as the product remains in the early stages of its commercial launch. "The Company is not providing full‑year 2026 sales guidance for ZUSDURI at this time, as the product remains in the early stages of its commercial launch," the company said.
Jelmyto continued to perform strongly, with underlying demand sales growing 7% year‑over‑year. Management guided 2026 Jelmyto sales to $97–$101 million, reflecting confidence in sustained demand for the drug. "Underlying demand sales grew 7% year-over-year," the company said.
UroGen’s cash position remains robust, with $120.5 million in liquid assets at year‑end. The company also secured a new $200 million term loan through Pharmakon Advisors, extending its debt maturity and providing additional non‑dilutive capital to support its growth initiatives. "UroGen ended 2025 with $120.5 million in cash, cash equivalents, and marketable securities," the company said.
The market reacted positively to the results, with UroGen’s stock rising in pre‑market trading. Analysts highlighted the debt refinancing and the momentum of the ZUSDURI launch as key tailwinds, while noting the Q4 revenue miss and widening net loss as headwinds that the company is addressing through cost discipline and strategic investment in its pipeline.
The company’s CEO, Liz Barrett, described 2025 as a "tremendously successful and transformative year for UroGen, highlighted by the FDA approval and commercial launch of ZUSDURI, the first and only approved medicine for adults with recurrent low‑grade intermediate‑risk non‑muscle invasive bladder cancer (LG‑IR‑NMIBC)."
The company also emphasized its commercial team’s enthusiasm: "Our commercial team is enthusiastically executing the ZUSDURI launch plan as we scale the organization to address the estimated $5 billion+ market opportunity."
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.